36 results
Thumbnail

D3.126 - Evaluation of Severe Pediatric Asthma Response to Biologics Using the Pediatric CONFiRM Score: A Real-Life Cohort Analysis

Thumbnail

D3.127 - Evaluation of Serum Ezrin Levels and Spirometric and Plethysmographic Tests in Patients with Allergic and Non-Allergic Asthma

Thumbnail

D3.128 - Management of Nasal Polyposis in Moderate-Severe Asthma Patients With Aspirin Desensitization And Biologic Agent Combination: Our Real-Life Experience With Seven Cases

Thumbnail

D3.129 - Evaluation of Cardiovascular Disease Risk and Associated Factors in Childhood Asthma

Thumbnail

D3.130 - PGI2 Signaling Attenuates the Proliferation and Type 2 Cytokine Production of Group 2 Innate Lymphoid Cells

Thumbnail

D3.131 - Comparative Assessment of Exercise Provocation, and Impulse Oscillometry in Young Adults With Exercise-Induced Respiratory Symptoms

Thumbnail

D3.132 - The impact of biological therapy on the quality of life of patients with severe asthma

Thumbnail

D3.133 - Clinical Impact of Cumulative Oral Corticosteroid Exposure in Patients with Severe Asthma: Data from the Korean Severe Asthma Registry

Thumbnail

D3.134 - Pulmonary rehabilitation at altitude: Is there an optimal season?

Thumbnail

D3.135 - Real World Efficacy of Benralizumab Treatment in Severe Eosinophilic Asthma: A Single-Center Experience

Thumbnail

D3.137 - The “Street Cat” Paradox: Low Prevalence but High Disease Burden of Mouse Sensitization in Pediatric Asthma

Thumbnail

D3.138 - Can FeNO predict lung function decline in asthma? A 5-year multicenter cohort study

Thumbnail

D3.139 - Asthma control and medication adherence in patients with asthma using preferred versus alternative GINA treatment tracks - a real-world observational study

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria